Back
Speaker illustration

Doctor Pedro Moliner

Bellvitge University Hospital, Hospitalet De Llobregat (Spain)

Member of:

European Society of Cardiology
Heart Failure Association

Pedro Moliner MD PhD, is consultant cardiologist in South Metropolitan Barcelona Integrated Heart Failure Programme and Cardio-Oncology Unit, Bellvitge University Hospital, Barcelona. Postdoctoral researcher in the BIO-HEART Cardiovascular diseases research group, IDIBELL (Bellvitge Biomedical Research Institute). He is member of the Council of Cardio-Oncology of the Spanish Society of Cardiology and the European Society of Cardiology, and also Fellow of the International Cardio-Oncology Society (FICOS). Dr. Moliner is the current head of the Cardio-Oncology Unit at the HUB-ICO Campus. This is a multidisciplinary unit created as a joint effort between Bellvitge University Hospital and Catalan Institute of Oncology to provide comprehensive cardiovascular care to patients with cancer.

Presentations

Soluble transferrin receptor as a marker of tissue iron deficiency: impact on health-related quality of life in patients with heart failure without systemic iron deficiency or anaemia

Event: ESC Congress 2023

Topic: Comorbidities

Session: Comorbidities and heart failure: cause and effect

Access
Like
Thumbnail

Soluble transferrin receptor as a marker of tissue iron deficiency: impact on exercise capacity and functional class in patients with heart failure without systemic iron deficiency or anaemia

Event: ESC Congress 2023

Topic: Comorbidities

Session: Comorbidities and heart failure: cause and effect

Access
Like
Thumbnail

Causes of death in a heart failure clinic in Spain along 17 years

Event: ESC Congress 2019

Topic: Epidemiology, Prognosis, Outcome

Session: Real world heart failures populations

Access
Like
Thumbnail

Multimarker panel of cardiac biomarkers in patients with heart failure and mid-range ejection fraction

Event: ESC Congress 2017

Topic: Heart failure, other

Session: Best Posters in HFpEF

Access
Like
Thumbnail

Prognostic value of a panel of biomarkers in heart failure with mid-range ejection fraction

Event: ESC Congress 2017

Topic: Prognosis

Session: Chronic heart failure (CHF)

Access
Like
Thumbnail

Frailty, co-morbidities and survival in heart failure patients with mid-range ejection fraction

Event: ESC Congress 2017

Topic: Heart failure, other

Session: Acute heart failure (AHF)

Access
Like
Thumbnail

Biomarker prognostic value in heart failure with mid-range ejection fraction

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Prognosis (using biomarkers)

Session: Biomarkers

Access
Like
Thumbnail

Co-morbidities and fragility are determinants of survival in patients with heart failure and mildly reduced ejection fraction

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: co-morbidities (other)

Session: Comorbodities

Access
Like
Thumbnail

Biomarker profiling in heart failure with mid-range ejection fraction

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Biomarkers, other

Session: Moderated Poster session 3 - Diagnosis

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources